B

Financial Toxicity of TKIs in NSCLC: Impact of TKI Out-of-Pocket Costs on Pts Outcomes

By Bernardo Goulart
217 views
March 26, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Cleveland Clinic Respiratory Institute

Advanced Diagnostic Bronchoscopy Workshop

Fri, Jun 14, 2024
Fox Chase Cancer Center

2024 Atlantic Regional Hematopathology Meeting

Sat, May 11, 2024
Penn Medicine Abramson Cancer Center

Updates in Oncology 2024 Philadelphia: with Proceedings from Interna…

Wed, Jun 12, 2024
UChicago Medicine

27th University of Chicago Comprehensive Cancer Center Developmental…

Fri, May 10, 2024
Vanderbilt University Medical Center (VUMC)

Vanderbilt Stem Cell Transplant and Cellular Therapy Symposium

Sat, May 11, 2024
Yale Cancer Center

Gastrointestinal Cancer CME Series: Gastroesophogeal Cancer

Thu, May 23, 2024
See 1 other
COR2ED The Heart of Medical Education

Precision Oncology in Practice - The Journey from Testing to Treatme…

Tue, Apr 30, 2024
See 1 other
European Research Initiative on CLL - ERIC

ERIC International Meeting 2024 - New Frontiers in CLL Research

Thu, Sep 26, 2024
i3 Health

Live Webinar: Hitting the Target in HER2-Positive Metastatic Colorec…

Mon, Apr 29, 2024
See 2 others
MI&T Congressi

3rd International Summit on Lung Cancer

Sun, May 5, 2024
SOHO Brazil

SOHO Brazil 2024

Thu, May 16, 2024
Total Health

MDONS Metro Denver Chapter Conference

Fri, May 17, 2024
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
35:40
Balazs Halmos

Year in Review: Lung Cancer

27:04
Fengting Yan

Cancer Screening Molecular Tools

08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
14:49
Vivek Subbiah

Year in Review: Precision Medicine

26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
05:02
GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson
11:50
GRACE

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

Feat. J. Rotow
22:57
Total Health

Lung Cancer Screening - Best of Lung 2023

Feat. C. Olazagasti
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
54:26
Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst
07:27
Jason Levy

Opus One: Final Results - RFA in Axial Skeleton